Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching
This analysis found no evidence of a statistically significantly increased risk of prostatitis among adult male patients with T2DM receiving canagliflozin compared with the other AHAs evaluated in this study.
Authors
- Saberi Rana Ali (ORCID: https://orcid.org/0009-0009-1581-8431)
- Anthony G. Sena (ORCID: https://orcid.org/0000-0001-8630-5347)
- Martijn J. Schuemie (ORCID: https://orcid.org/0000-0002-0817-5361)
- Yuan Zhong (ORCID: https://orcid.org/0000-0002-3241-4924)
- Patrick B Ryan
- Carolyn Jeffcoat (ORCID: https://orcid.org/0000-0002-5843-6398)
- Sergio A. Fonseca
Institutions
- Johnson & Johnson (United States) (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1371/journal.pone.0341745
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00